Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + docetaxel + fluorouracil + leucovorin + oxaliplatin + sintilimab
- Development stage
- Unknown
- Lead developer
- Second Hospital of Lanzhou University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a chemo-immunotherapy combination regimen being investigated for the perioperative treatment of locally advanced gastric adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma. It combines the FLOT chemotherapy backbone (docetaxel, oxaliplatin, fluorouracil, and leucovorin) with sintilimab, a PD-1 monoclonal antibody, and apatinib, a small-molecule tyrosine kinase inhibitor targeting VEGFR-2. The rationale is to combine the cytotoxic effects of chemotherapy with the immune checkpoint inhibition of sintilimab and the anti-angiogenic properties of apatinib to improve pathological complete response (pCR) rates and survival outcomes. The regimen is primarily associated with clinical trials conducted by Lanzhou University Second Hospital.
- Other names
- Sintilimab plus Apatinib plus FLOTFLOT-ASSintilimab + Apatinib + FLOT
02
Targets
DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on apatinib + docetaxel + fluorouracil + leucovorin + oxaliplatin + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + docetaxel + fluorouracil + leucovorin + oxaliplatin + sintilimab.